Remarkable Improvement in a Patient with Idiopathic Pulmonary Fibrosis after Treatment with Nintedanib
Remarkable Improvement in a Patient with Idiopathic Pulmonary Fibrosis after Treatment with Nintedanib
复制标题
DOI：
10.2169/internalmedicine.1890-18
复制
发表时间：
2019-01-01
影响因子：
1.2
通讯作者：
Niimi, Akio
中科院分区：
文献类型：
--
作者：
Nakano, Akiko;Ohkubo, Hirotsugu;Niimi, Akio
在之前的随机试验中，尼达尼布已被证明可以显着降低特发性肺纤维化（IPF）患者用力肺活量（FVC）的年下降率。一名 71 岁男子出现劳力性呼吸困难，被诊断患有 IPF。尼达尼布治疗四个月后，高分辨率计算机断层扫描结果显示磨玻璃样混浊和实变区域减少；治疗13个月后，FVC从3.07 L改善至3.43 L，血清Krebs von den Lungen (KL)-6浓度下降至正常水平。我们在此报告了一名 IPF 患者，他被认为是对尼达尼布的超级反应者。
Nintedanib has been shown to significantly reduce the annual rate of decline in the forced vital capacity (FVC) in patients with idiopathic pulmonary fibrosis (IPF) in previous randomized trials. A 71-year-old man developed exertional dyspnea and was diagnosed with IPF. Four months after treatment with nintedanib, high-resolution computed tomography findings revealed reduced areas of ground-glass opacity and consolidation; 13 months after treatment, the FVC showed improvement from 3.07 to 3.43 L, and the serum Krebs von den Lungen (KL)-6 concentration showed a decline to normal levels. We herein report a patient with IPF who was considered a super responder to nintedanib.